 |
Indication & Dosage |
| |
| |
| Oral |
| ADVANCED OVARIAN CARCINOMA |
| Adult:
When used as a single agent in previously untreated patients, 400 mg/m2 BSA by IV infusion over 15-60 min on day 1 at 4-wkly intervals. May repeat course if neutrophil count is at least 2000 and platelet count is at least 100,000. For use as a single agent in previously treated patients, initiate at 360 mg/m2. When used with cyclophosphamide in previously untreated patients, initiate at 300 mg/m2. |
|
| |
|
| Precautions |
Neonates; diminished renal function; neurotoxicity; liver function impairment. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Thrombocytopenia, neutropenia, leukopenia, anaemia; nausea, vomiting, central neurotoxicity, peripheral neuropathies, ototoxicity; elevation of ALT, AST, blood urea and bilirubin levels, electrolyte disturbances; alopecia; asthenia, pain; cardiac failure, embolism and cerebrovascular accidents may occur; mucositis. |
| |
|
| Adverse Drug Reactions |
Bone marrow suppression and anaphylactic reactions. |
| |
|
| Interactions |
Increased risk of ototoxicity when used with aminoglycosides. |
| |
|
|
|
